Send to

Choose Destination
Drug Discov Today. 2002 Jun 15;7(12):653-63.

NF-kappa B: arresting a major culprit in cancer.

Author information

Department of Inflammatory Disease, Johnson & Johnson Pharmaceutical R&D, A Division of Janssen Pharmaceutica, Turnhoutseweg 30, 2340 Beerse, Belgium.


Nuclear factor-kappa B (NF-kappa B) has long been known to play a central role in the immune system by regulating the expression of key genes. Moreover, activation of this transcription factor helps a wide variety of cell types survive damage induced by pro-apoptotic stimuli. Because of its crucial role in the regulation of pro-inflammatory genes, NF-kappa B is a promising target for the discovery of anti-inflammatory drugs. More recently, NF-kappa B has also emerged as a major culprit in a variety of human cancers mainly because of its ability to protect transformed cells from apoptosis. The pharmaceutical industry should, therefore, seriously consider testing inhibitors of NF-kappa B, identified as part of their anti-inflammatory drug discovery programs, in combination with other chemotherapeutic drugs in models of cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center